New directions in the treatment of cancer: Inhibition of signal transduction

Journal of Pharmacy Practice

Volumn 15, Issue 1, 2002, Pages 5-16

  Finley, Rebecca S ^a  

^a UNIVERSITY OF THE SCIENCES   (United States)

Author keywords

Antiangiogenesis; Cancer treatment; Epidermal growth factor; Receptor; Signal transduction

Indexed keywords

3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CARBOPLATIN; CETUXIMAB; CIPROFLOXACIN; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GEMCITABINE; IMMUNOTOXIN; IRINOTECAN; L 778123; LAPATINIB; LONAFARNIB; MDX 447; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY H22 EGF; PACLITAXEL; PANITUMUMAB; PROTEIN FARNESYLTRANSFERASE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RALTITREXED; RETINOID; TIPIFARNIB; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACNE; ARTICLE; BONE MARROW SUPPRESSION; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CELL SURFACE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COLON CARCINOMA; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; ENZYME INHIBITION; GENE OVEREXPRESSION; HEADACHE; HUMAN; INHIBITION KINETICS; METASTASIS POTENTIAL; NEUTROPENIA; PROGNOSIS; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; SKIN DEFECT; TUMOR SUPPRESSOR GENE;

EID: 0036082185     PISSN: 08971900     EISSN: None     Source Type: Journal    
DOI: 10.1106/CJ0V-JB04-VBD4-V65D     Document Type: Article

References (124)

1. Role of an antiepidermal growth factor receptor in treating cancer
2. Cell signaling by receptor tyrosine kinases
3. Receptor tyrosine kinases: Specific outcomes from general signals
4. Epidermal growth factor-related peptides and their receptors in human malignancies
5. Transforming growth factors and related peptides in gastrointestinal neoplasia
6. Growth factors and oncogenes in human gastrointestinal carcinomas
7. Growth factors and cancer
8. The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer
9. Expression of epidermal growth factor (EGF) and epidermal growth factor receptor (EGFR) in gastric and colorectal carcinomas: An immunohistological study of 63 cases
10. Epidermal growth factor receptor as a target for therapy with antireceptor monoclonal antibodies
11. The EGF receptor system as a target for antitumor therapy
12. Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents
13. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in human tumor xenograft model
14. Altered cell cycle distribution and cyclin-CDK protein expression in A431 epidermoid carcinoma cells treated with doxorubicin and a chimeric monoclonal antibody to the epidermal growth factor receptor
15. Antitumor and cell cycle responses in KB cells treated with a chimeric anti-EGFR monoclonal antibody in combination with cisplatin
16. Antitumor activity of sequential treatment with topotecan and antiepidermal growth factor receptor monoclonal antibody C225
17. Immunochemotherapy of human transitional cell carcinoma (TCC) with anti-EGF-R monoclonal antibody (Mab) C225 and the anti-cancer drugs, Taxol™ and cisplatinum
18. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck
19. Regression of human pancreatic carcinoma growth orthotopically in athymic nude mice by blockade of epidermal growth factor receptor (EGF-R) signaling in combination with gemcitabine
20. Antitumor effects of antiepidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts
21. EGFR and steroid receptors in ovarian carcinoma: Comparison with prognostic parameters and outcome of patients
22. Growth inhibition of human colorectal carcinoma xenografts by anti-EGF receptor monoclonal antibody IMC-C225 in combination with irinotecan
23. Antitumour activity of combined blockade of epidermal growth factor receptor and protein kinase A
24. Neutralizing antibodies against epidermal growth factor and erbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo
25. Antiepidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice
26. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms
27. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody
28. Monoclonal antibody (MoAb) IMC-C225, an antiepidermal growth factor receptor (EGFr), for patients (pts) with EGFr-positive tumors refractory to or in relapse from previous therapeutic regimens
29. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR)
30. A phase I study of chimerized antiepidermal growth factor receptor (EGFr) monoclonal antibody, C225 in combination with cisplatin (CDDP) in patients (pts) with recurrent head and neck squamous cell carcinoma (SCC)
31. A phase I study of antiepidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer
32. Safety profile of the monoclonal antibody (MoAb) IMC-C225, an antiepidermal growth factor receptor (EGFr) used in the treatment of EGFr-positive tumors
33. ABX-EGF: A fully humanized anti-EGF receptor antibody in patients with advanced cancer
34. A phase I trial of the epidermal growth factor receptor (EGFR)-directed bispecific antibody (BsAB) MDX-447 in patients with solid tumors
35. Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily
36. Protein tyrosine kinase inhibitors as novel therapeutic agents
37. Inhibitors of tyrosine kinase
38. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor
39. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD 1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor
40. Potentiation of cytotoxic agents against human tumors in mice by ZD 1839 (Iressa™), an inhibitor of EGFR tyrosine kinase, does not require high levels of expression of EGFR
41. A phase I intermittent dose-escalation trial of ZD1839 (Iressa) in Japanese patients with solid malignant tumours
42. Final results of a phase I intermittent dose-escalation trial of ZD1839 ('Iressa') in Japanese patients with various solid tumours
43. Intermittent oral AD 1839 (Iressa), a novel oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), shows evidence of good tolerability and activity: Final results from a phase I study
44. Continuous administration of ZD1839 (Iressa), a novel oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected tumor types: Evidence of activity and good tolerability
45. Therapy of human carcinomas in athymic mice by inhibition of EGF receptor-mediated signal transduction with CP-358774: Dynamics of receptor inhibition and anti-tumor effects
46. 18FDG-PET evaluation of patients treated with the epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor, CP-358,774
47. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies
48. A phase II trial of the epidermal growth factor receptor tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients with advanced, EGFR-expressing, non-small cell lung cancer
49. Phase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced ovarian cancer
50. Phase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced squamous cell carcinoma of the head and neck
51. Protein farnesyl transferase inhibitors block the growth of ras-dependent tumors in nude mice
52. The potential of farnesyltransferase inhibitors as cancer chemotherapeutics
53. Novel noncytotoxic anticancer agents: Signal transduction inhibitors
54. Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to Taxol and epothilones
55. Phase I and pharmacologic study with the novel farnesyltransferase inhibitor (FTI) R115777
56. A phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced breast cancer
57. A phase I and pharmacokinetic (PK) study of the farnesyltransferase inhibitor, R115777 in combination with gemcitabine
58. A phase I, clinical and pharmacokinetic (PK) trial of farnesyl transferase inhibitor (FTI) R115777 + docetaxel: A promising combination in patients (PTS) with solid tumors
59. Enhanced myelosuppression of topotecan when combined with the farnesyl transferase inhibitor, R115777: A phase I & pharmacodynamic study
60. Use of a farnesyl transferase inhibitor R115777 in relapsed and refractory acute leukemias: Preliminary results of a phase I trial
61. Pharmacokinetics (PK) and pharmacodynamics (PD) of the farnesyltransferase (FT) inhibitor BMS-214662 in patients with advanced solid tumors
62. Phase I study of farnesyl transferase inhibitor, BMS-214662 in solid tumors
63. Phase I clinical trial of the farnesyltransferase (FT) inhibitor BMS-214662 in patients with advanced solid tumors
64. Principles of Cdk regulation
65. A phase I trial of 1 hour infusion of flavopiridol (FLA), a novel cyclin-dependent kinase inhibitor, in patients with advanced neoplasms
66. A phase I and pharmacologic study of UCN-01, a protein kinase C inhibitor
67. Control of oncogene expression by antisense nucleic acids
68. Phase I clinical and pharmacokinetic study of Bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma
69. C-raf-1 depletion and tumor responses in patients treated with the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A)
70. Phase I/pharmacokinetic trial of the novel thioxanthone SR233377 (WIN33377) on a 5-day schedule
71. Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer
72. Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies
73. Bcl-2 and the regulation of programmed cell death
74. Investigations of antisense oligonucleotides targeted against bcl-2 RNAS
75. A phase I/II trial of ISIS 3521, an antisense inhibitor of protein kinase C alpha combined with carboplatin and paclitaxel in patients with non-small cell lung cancer
76. Phase I/II trial of ISIS 3521, an antisense inhibitor of PKC-alpha, with carboplatin and paclitaxel in non-small cell lung cancer
77. A phase I study of BCL-2 antisense G3139 (GENTA) and weekly docetaxel in patients with advanced breast cancer and other solid tumors
78. A phase I trial of G3139 (Genta, Inc), a BCL2 antisense drug, by continuous infusion (CI) as a single agent and with weekly Taxol (T)
79. A phase I trial of an antisense oligonucleotide to BCL-2 (G3139, Genta) and mitoxantrone in patients with metastatic hormone refractory prostate cancer (HRPC)
80. What is the evidence that tumours are angiogenesis dependent?
81. The relationship between cell proliferation and the vascular system in a transplanted mouse mammary tumour
82. Current pathological methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors
83. Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastasis and survival in breast cancer
84. Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity
85. Prognostic significance of the microvascular count in colorectal cancer
86. Relation of neovascularisation to metastasis of non-small cell lung cancer
87. Microvessel count and cerebrospinal fluid basic fibroblast growth factor in children with brain tumours
88. Antivascular therapy: A new approach to cancer treatment
89. Tumor cells secrete a vascular permeability factor that promotes the accumulation of ascites fluid
90. A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines
91. Elevated levels of an angiogenic peptide, basic fibroblasts growth factor, in the urine of patients with a wide spectrum of cancers
92. Antiangiogenesis for cancer therapy
93. The implications of angiogenesis for the biology and therapy of cancer metastasis
94. Antiangiogenic therapy of transgenic mice impairs de-novo tumor-growth
95. Inhibition of vascular endothelial growth factor-induced angiogenesis supresses tumour growth in vivo
96. A secreted FGF-binding protein can serve as the angiogenic switch in human cancer
97. Phase I trial of SU5416 a novel angiogenesis inhibitor in patients with advanced malignancies
98. Phase I trial of recombinant humanized anti vascular endothelial growth factor in patients with metastatic cancer
99. A phase II trial of single-agent Rhumab VEGF (recombinant humanized monoclonal antibody to vascular endothelial growth factor) in patients with relapsed metastatic breast cancer
100. A randomized phase II trial comparing rhuMAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus 5-fluorouracil/leucovorin (FU/LV) to FU/LV alone in patients with metastatic colorectal cancer
101. A randomized phase II trial comparing Rhumab VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIB/IV NSCLC
102. Results of a phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies
103. A phase I trial ofthe VEGF inhibitor SU5416, incorporating dynamic contrast MRI assessment of vascular permeability
104. A multicenter dose-escalating study of SU5416 in AIDS-related Kaposi's sarcoma
105. A phase I/II study of SU5416 in combination with 5-FU/leucovorin in patients with metastatic colorectal cancer
106. Angiostatin induces and sustains dormancy of human primary tumors in mice
107. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
108. Antiangiogenic therapy of experimental cancer does not induce drug resistance
109. Cytostatic inhibition of endothelial cell growth by the angiogenesis inhibitor TNP-470 (AG-1470)
110. Phase I study and assessment of bioactivity of 120-hour infusion of TNP-470 in patients with advanced cancer
111. Fumagillin analog in the treatment of Kaposi's sarcoma: A phase I AIDS Clinical Trial Group study-AIDS Clinical Trial Group No. 215 Team
112. A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix
113. A study of TNP-470 in patients with advanced cancer
114. Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal cell carcinoma
115. Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small cell lung cancer: Amphiregulin and microvessel count are independent prognostic indicators of survival
116. A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer
117. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: A review on 5232 patients
118. Expression of epidermal growth factor receptor mRNA and protein in primary breast carcinomas
119. Expression analyses of epidermal growth factor receptor and HER-2/neu: No advantage of prediction of recurrence or survival in breast cancer patients
120. EGF-R expression in ductal breast cancer: Proliferation and prognostic implications
121. Quantitative immunohistochemical analysis of transforming growth factor α and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck
122. EGF, TGF α, and EGF-R in human colorectal adenocarcinoma
123. The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer